Skip to search formSkip to main content

alemtuzumab Injection [Lemtrada]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system which leads to demyelination and neurodegeneration… Expand
Is this relevant?
2019
2019
Pneumocystis jirovecii pneumonia (PJP) is a known risk in patients with chronic lymphocytic leukemia treated with alemtuzumab… Expand
Is this relevant?
2018
2018
Alemtuzumab (Lemtrada®) is a monoclonal antibody recognizing CD52 that selectively depletes T- and B-lymphocytes1 and is… Expand
Is this relevant?
2018
2018
Alemtuzumab (Lemtrada®) is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting… Expand
  • figure 1
Is this relevant?
Review
2017
Review
2017
Alemtuzumab (Lemtrada®) is a humanized anti-CD52 IgG1 monoclonal antibody that depletes CD52-expressing cells from the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
U pstream targeting of both T and B cells is a rational therapeutic approach in multiple sclerosis (MS) in view of how both cell… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Review
2016
Review
2016
Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union… Expand
  • table 1
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?
2016
2016
BackgroundAlemtuzumab (Lemtrada®) is a newly approved therapeutic agent for relapsing-remitting multiple sclerosis (RRMS). In… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2016
2016
Twenty-four approved monoclonal antibodies (mAbs) not indicated for cancer therapy are specific for a total of 20 different… Expand
Is this relevant?
2014
2014
End of December 2013, alemtuzumab, a monoclonal antibody for multiple sclerosis (MS) with an immunomodulator action targeting… Expand
Is this relevant?